Most common adverse events during treatment (number of patients)
| Lam/interferon (n=76) |
Interferon (n=70) | Lamivudine (n=84) | |
| Viral respiratory infections | 32 | 37 | 25 |
| Headache | 711-150 | 47 | 271-151 |
| Muscle pain | 36 | 40 | 111-151 |
| Abdominal discomfort and pain | 11 | 23 | 13 |
| Diarrhoea | 14 | 16 | 13 |
| Malaise and fatigue | 66 | 70 | 351-151 |
| Arthralgia | 9 | 23 | 4 |
| Anorexia | 30 | 33 | 41-151 |
| Dizziness | 9 | 19 | 8 |
| Nausea and vomiting | 33 | 34 | 19 |
| Fever/chills | 46 | 43 | 61-151 |
| Hair loss and alopecia | 30 | 21 | 81-151 |
Most common adverse events defined as those occurring during treatment in ⩾15% of patients in any treatment group.
↵1-150 p value: lam/interferon v interferon: 0.004 (borderline significant in view of multiple testing);
↵1-151 p value lam/interferon v lamivudine: <0.002 (significant after correction for multiple testing).